Detalhe da pesquisa
1.
Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate risk-1 myelodysplastic syndrome.
Haematologica
; 105(12): 2785-2794, 2020 12 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33256377
2.
Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug.
Blood
; 123(12): 1818-25, 2014 Mar 20.
Artigo
Inglês
| MEDLINE | ID: mdl-24345753
3.
Eltrombopag and improved hematopoiesis in refractory aplastic anemia.
N Engl J Med
; 367(1): 11-9, 2012 Jul 05.
Artigo
Inglês
| MEDLINE | ID: mdl-22762314
4.
Lung Cancer Genomics.
Acta Med Acad
; 48(1): 78-83, 2019 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-31264435
5.
Response to rapamycin analogs but not PD-1 inhibitors in PTEN-mutated metastatic non-small-cell lung cancer with high tumor mutational burden.
Lung Cancer (Auckl)
; 9: 45-47, 2018.
Artigo
Inglês
| MEDLINE | ID: mdl-29844707
6.
Incidence and clinical significance of ESR1 mutations in heavily pretreated metastatic breast cancer patients.
Onco Targets Ther
; 8: 3323-8, 2015.
Artigo
Inglês
| MEDLINE | ID: mdl-26648736
7.
Long-term outcomes in myelodysplastic syndrome patients treated with alemtuzumab.
Blood Adv
; 3(7): 980-983, 2019 04 09.
Artigo
Inglês
| MEDLINE | ID: mdl-30936058
8.
Treatment of Patients With Lobular Breast Cancer Harboring Human Epidermal Growth Factor Receptor 2 Mutation With HER2-Directed Therapy.
JCO Precis Oncol
; 2: 1-7, 2018 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-35135147
9.
Immunomodulatory treatment of myelodysplastic syndromes: antithymocyte globulin, cyclosporine, and alemtuzumab.
Semin Hematol
; 49(4): 304-11, 2012 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-23079060